Associated Papers
Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations.
Sakuma M et al.
Leukemia, 2025
Rapid clinical deployment of UBA1 testing in patients with VEXAS syndrome.
Wadsworth PA et al.
American Journal of Clinical Pathology, 2025
Clonal hematopoiesis meets an autoinflammatory disease: the new paradigm of VEXAS syndrome.
Fiumara M et al.
Expert Review of Hematology, 2025
Rapid Screening and Monitoring of UBA1 Mutations in VEXAS Syndrome.
Martín Castillo I et al.
The Journal of Molecular Diagnostics : Jmd, 2025
VEXAS syndrome: A newly identified X-Linked hematoinflammatory disorder - A comprehensive overview of its genetic, molecular, inflammatory, and clinical landscape.
Singh A et al.
Journal of Autoimmunity, 2025
VEXAS: A review of current understandings and emerging treatment strategies.
Holden R et al.
Frontiers in Immunology, 2025
VEXAS without vacuoles: Linking genotype to phenotype.
Zhukovsky S et al.
Ejhaem, 2024
Distinct bone marrow findings associated with a noncanonical UBA1 variant in VEXAS syndrome.
Allison DR et al.
American Journal of Hematology, 2024
Shared and distinct mechanisms of UBA1 inactivation across different diseases.
Collins JC et al.
The Embo Journal, 2024
VEXAS syndrome: Clinical, hematologic features and a practical approach to diagnosis and management.
Koster MJ et al.
American Journal of Hematology, 2024
Shared and Distinct Mechanisms of UBA1 Inactivation Across Different Diseases.
Collins JC et al.
Biorxiv : the Preprint Server for Biology, 2023
Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies.
Sakuma M et al.
Leukemia, 2023
36823397 (PubMed )
Supplement: 41375_2023_1857_MOESM3_ESM.xlsx › Supplementary_Table_3
Select a paper to view details